Bayer Aktiengesellschaft

XETRA BAYN.DE

Bayer Aktiengesellschaft Shareholders' Equity for the year ending December 31, 2023: USD 36.34 B

Bayer Aktiengesellschaft Shareholders' Equity is USD 36.34 B for the year ending December 31, 2023, a -12.39% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Bayer Aktiengesellschaft Shareholders' Equity for the year ending December 31, 2022 was USD 41.48 B, a 10.37% change year over year.
  • Bayer Aktiengesellschaft Shareholders' Equity for the year ending December 31, 2021 was USD 37.59 B, a 0.81% change year over year.
  • Bayer Aktiengesellschaft Shareholders' Equity for the year ending December 31, 2020 was USD 37.29 B, a -29.81% change year over year.
  • Bayer Aktiengesellschaft Shareholders' Equity for the year ending December 31, 2019 was USD 53.12 B, a 0.96% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
XETRA: BAYN.DE

Bayer Aktiengesellschaft

CEO Mr. William N. Anderson
IPO Date Dec. 16, 1996
Location Germany
Headquarters Kaiser-Wilhelm-Allee 1
Employees 96,931
Sector Health Care
Industries
Description

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Similar companies

BMW.DE

Bayerische Motoren Werke Aktiengesellschaft

USD 78.31

0.29%

SAP.DE

SAP SE

USD 254.97

2.05%

ALV.DE

Allianz SE

USD 304.65

1.19%

SIE.DE

Siemens Aktiengesellschaft

USD 199.90

1.01%

StockViz Staff

January 15, 2025

Any question? Send us an email